23 May 2026
In plain English
Quiet day across the protocol. The FDA's peptide advisory panel is 61 days out with all six empty seats still unfilled — nineteen weeks and counting since Health Secretary Kennedy committed to filling them. Hims & Hers (the telehealth company expected to launch a peptide product line this year) remains silent twelve days after quarterly earnings. The Medicare weight-loss drug program launching July 1 still has no final operational guidance at 39 days out. The biggest commercial data point: Eli Lilly's new oral weight-loss pill Foundayo hit roughly 17,000 prescriptions in its sixth week on the market, a 66% jump from the prior week and the fastest acceleration since launch — likely driven by insurance formulary activation. Meanwhile, GLP-1 Picks logged zero affiliate revenue for a third consecutive week of decline, with search positions sliding from 13 to 25. Everything else holds.
Signal detail
61 days to PCAC. Zero vacancy appointments in 19+ weeks. Historian: advisory-committee vacancy-absence reference class enters uncommon territory at 19+ weeks — but Kennedy's ACIP appointments took 4 weeks (Feb 27 2026), proving capacity exists. Timing of PCAC fills is unpredictable; batch appointments remain the most likely pattern. Skeptic: quorum risk persists — 4 of 12 seated, no chair. A PCAC without quorum cannot issue a formal recommendation, which would resolve the forecast TRUE by default. Bayesian: prior 0.55, posterior 0.55. No new evidence.
Same institutional dynamics. No USP monograph progress for any of four tracked peptides. Oral presentation deadline June 30 is the next signal-rich window — industry coalition presentations will reveal depth of organized support.
12 days post-Q1 earnings, no peptide launch announcement. Historian: California facility month 16 post-acquisition, within the 12–24 month M&A-to-launch cadence. Skeptic: diagnostics expansion and Canada entry divide corporate bandwidth. Q1 net loss $92.1M. FY guidance raised to $2.8–3.0B confirms business health but not peptide timeline. Bayesian: Foundayo ~17K Week 6 Rx confirms branded GLP-1 channel is printing — reduces urgency to diversify but doesn't cancel sunk-cost facility logic. Posterior 0.84.
No new adverse events. No new top-5 outlet features. Historian: institutional template positioning (ProPublica, ECRI, ISMP, academic papers) stable at late build-phase, month 2–3 of pipeline. Base rate: once templates are positioned, top-5 outlet features follow within 3–12 months in ~60% of cases. Augur: TRIUMPH-1 dysesthesia coverage (Day 2) expands the "drug side effects" media frame — adjacent genre conditioning, not a trigger.
39 days to July 1 launch. CMS operational silence continues — spring 2026 guidance still undelivered at T-39. Historian: CMS operational silence at T-39 is weakly directional for slow-ramp. Part D initial rollout showed operational details finalized at T-30 in many plans — still within window. Bayesian: Foundayo Week 6 ~17K Rx confirms underlying branded demand but doesn't touch Bridge enrollment mechanics. Posterior 0.72.
No new peptide DTC affiliate programs. First-party data: $0 payout, 0 conversions — third consecutive declining week. GLP-1 CPA dominance ($260 vs $8–40) is structural but denominator approaching zero at current trajectory. Math trivially holds when both numerator and denominator are zero.
compound-peptide-property-live: holds 0.85, flagged. Eighth consecutive day flagged for formal resolution. Per operator clarification 2026-05-15, the broader portfolio-ship thesis is satisfied. Recommend operator resolve TRUE and retire from daily re-evaluation.
How Barque got smarter today
- Foundayo trajectory as demand-signal validator. Week 6 re-acceleration after mid-May PBM activation confirms a pattern: oral GLP-1 adoption curves have a formulary-driven step function at ~Week 5–6, distinct from the linear trajectory of injectable launches. This pattern is now a reusable reference class for future oral drug launches (CagriSema, retatrutide oral formulation if pursued).
- Third week of glp1picks decline sharpens diagnosis frame. Position slip from 13 → 25 over three weeks, impressions -57%, $0 payout. Consistent with algorithmic penalty, index coverage loss, or competitive displacement. Revenue signal ($749 → $16 → $0) is fully downstream of position loss, not a separate phenomenon. RESEARCH work order escalation from yesterday is the right next step.
- Firehose silence persists. Second day of zero overnight captures. During a week with TRIUMPH-1 coverage, zero captures is a system failure, not a quiet news cycle. Listener health verification is now an operational priority.
- Voice calibration. All four voices converged within 0.02 on every forecast today. Council performing correctly on low-signal days — producing maintenance output, not inventing movement.
- Sources sampled. Tier 1: FDA.gov (PCAC roster, advisory calendar), CMS.gov, Eli Lilly IR, Fierce Pharma, AJMC, PRNewsWire, HCPLive. Tier 2 (rotated): SEC EDGAR (Akston FWP), CatCognition (MEOW-1), PeptideEffect (search trend report), Newsweek/Smithsonian (MEOW-1 coverage). Tier 3: Glossy, GoodRx, TechTimes. First-party: Katalys + GSC (May 22 aggregation).